Aminocaproic acid (injection): Difference between revisions

Revision as of 21:44, 29 January 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here.

Overview

Aminocaproic acid (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the amino acid lysine, which makes it an effective inhibitor for enzymes which bind that particular residue. Such enzymes includeproteolytic enzymes (which break down proteins) including plasminogen, the enzyme responsible for fibrinolysis. For this reason it is effective in treatment of some bleeding disorders and is marketed as Amicar.

US Brand Names

AMICAR^®

FDA Package Insert

Mechanism of Action

Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine analogue, it binds reversibly to the kringle domain of the enzyme plasminogen and blocks binding of fibrin, which is normally activated to plasmin.

References

Template:WikiDoc Sources

@@ Line 1: / Line 1: @@
-{{drugbox
+__NOTOC__
-| IUPAC_name = 6-aminohexanoic acid
+{{XXXXX}}
-| image = 6-Aminocaproic acid.png
-| CAS_number = 60-32-2
-| ATC_prefix = B02
-| ATC_suffix = AA01
-| ATC_supplemental =
-| PubChem = 564
-| DrugBank = APRD00791
-| C=6 | H=13 | N=1 | O=2
-| molecular_weight = 131.173 g/mol
-| bioavailability =
-| protein_bound =
-| metabolism = [[Renal]]
-| elimination_half-life = 2 hours
-| pregnancy_category =
-| legal_status =
-| routes_of_administration =
-}}
-{{SI}}
 {{CMG}}
+'''''For patient information, click <u>[[XXXXX (patient information)|here]]'''''</u>.
+==Overview==
-'''Aminocaproic acid''' (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the [[amino acid]] [[lysine]], which makes it an effective [[enzyme inhibitor|inhibitor]] for [[enzyme|enzymes]] which bind that particular residue. Such enzymes include [[proteolytic]] enzymes (which break down [[protein|proteins]]) including [[plasminogen]], the enzyme responsible for [[fibrinolysis]]. For this reason it is effective in treatment of some [[coagulopathy|bleeding disorders]] and is marketed as Amicar.
+'''Aminocaproic acid''' (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the [[amino acid]][[lysine]], which makes it an effective [[enzyme inhibitor|inhibitor]] for [[enzyme|enzymes]] which bind that particular residue. Such enzymes include[[proteolytic]] enzymes (which break down [[protein|proteins]]) including [[plasminogen]], the enzyme responsible for [[fibrinolysis]]. For this reason it is effective in treatment of some [[coagulopathy|bleeding disorders]] and is marketed as Amicar.
-==Mechanism of action==
-Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine [[analogue]], it binds reversibly to the [[kringle domain]] of the enzyme [[plasminogen]] and blocks binding of [[fibrin]], which is normally activated to [[plasmin]].
-==Clinical use==
+==Category==
-Aminocaproic acid is used to treat excessive postoperative bleeding.  It can be given orally or intravenously.  One scenario where it may be useful is to treat bleeding after dental extractions in patients with [[hemophilia]], because the [[oral mucosa]] is rich in plasminogen activators.  A meta-analysis found that lysine analogs like aminocaproic acid significantly reduced blood loss in patients undergoing coronary artery bypass grafting.
+Antifibrinolytics
+==US Brand Names==
+AMICAR<sup>®</sup>
-===Side effects===
+==FDA Package Insert==
-Its side effects are mainly related to the [[gastrointestinal tract]] and include nausea, vomiting, abdominal pain, and diarrhea. It may cause generalised [[myalgia]]. The main risk associated with aminocaproic acid is the increased risk for [[thrombosis]] because of the inhibition of fibrinolysis.
-==Other uses==
+''' [[XXXXX indications and usage|Indications and Usage]]'''
+'''| [[XXXXX dosage and administration|Dosage and Administration]]'''
+'''| [[XXXXX dosage forms and strengths|Dosage Forms and Strengths]]'''
+'''| [[XXXXX contraindications|Contraindications]]'''
+'''| [[XXXXX warnings|Warnings and Precautions]]'''
+'''| [[XXXXX adverse reactions|Adverse Reactions]]'''
+'''| [[XXXXX drug interactions|Drug Interactions]]'''
+'''| [[XXXXX use in specific populations|Use in Specific Populations]]'''
+'''| [[XXXXX overdosage|Overdosage]]'''
+'''| [[XXXXX description|Description]]'''
+'''| [[XXXXX clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[XXXXX nonclinical toxicology|Nonclinical Toxicology]]'''
+'''| [[XXXXX clinical studies|Clinical Studies]]'''
+'''| [[XXXXX how supplied storage and handling|How Supplied/Storage and Handling]]'''
+'''| [[XXXXX patient counseling information|Patient Counseling Information]]'''
+'''| [[XXXXX labels and packages|Labels and Packages]]'''
-Aminocaproic acid is occasionally used in [[BN-PAGE]] [[buffer solution|buffers]], not for its effects as a proteolysis inhibitor, but to solubilize [[membrane protein|membrane proteins]] in place of [[sodium chloride]] (which is incompatible with PAGE in the necessary concentration). Percent recovery of [[protein complex|protein complexes]] increases linearly with the concentration of inhibitor (between 125 mM and 750 mM)<ref>Schägger, H and Von Jagow, G (1991). Blue Native Electrophoresis for Isolation of Membrane Protein Complexes in Enzymatically Active Form. ''Analytical Biochemistry 199'' (2): 223-231.</ref>.
+==Mechanism of Action==
-==References==
-<references/>
+Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine [[analogue]], it binds reversibly to the [[kringle domain]] of the enzyme [[plasminogen]] and blocks binding of [[fibrin]], which is normally activated to [[plasmin]].
-{{Antihemorrhagics}}
+==References==
+{{Reflist|2}}
+[[Category:Antifibrinolytics]]
+[[Category:Cardiovascular Drugs]]
 [[Category:Amino acids]]
 [[Category:Antifibrinolytics]]